Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient

Severe acute respiratory syndrome coronavirus 2 has had an indelible effect, with 153,738,171 cases recorded globally as per the World Health Organization’s dashboard. The medical establishment is racing to find repurposed medications that can be successful against this novel coronavirus due to a sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Jadeja, Dhigishaba M, Patel, Nirmit R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189533/
https://www.ncbi.nlm.nih.gov/pubmed/34123627
http://dx.doi.org/10.7759/cureus.14928
_version_ 1783705517186613248
author Jadeja, Dhigishaba M
Patel, Nirmit R
author_facet Jadeja, Dhigishaba M
Patel, Nirmit R
author_sort Jadeja, Dhigishaba M
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 has had an indelible effect, with 153,738,171 cases recorded globally as per the World Health Organization’s dashboard. The medical establishment is racing to find repurposed medications that can be successful against this novel coronavirus due to a shortage of new drugs to treat the disease. Favipiravir, an antiviral drug originally developed for influenza, is one of the drugs that has recently received a lot of attention, particularly in India. Here, we present a case of favipiravir-induced drug fever in a young adult coronavirus disease 2019 patient.
format Online
Article
Text
id pubmed-8189533
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-81895332021-06-10 Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient Jadeja, Dhigishaba M Patel, Nirmit R Cureus Internal Medicine Severe acute respiratory syndrome coronavirus 2 has had an indelible effect, with 153,738,171 cases recorded globally as per the World Health Organization’s dashboard. The medical establishment is racing to find repurposed medications that can be successful against this novel coronavirus due to a shortage of new drugs to treat the disease. Favipiravir, an antiviral drug originally developed for influenza, is one of the drugs that has recently received a lot of attention, particularly in India. Here, we present a case of favipiravir-induced drug fever in a young adult coronavirus disease 2019 patient. Cureus 2021-05-09 /pmc/articles/PMC8189533/ /pubmed/34123627 http://dx.doi.org/10.7759/cureus.14928 Text en Copyright © 2021, Jadeja et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Jadeja, Dhigishaba M
Patel, Nirmit R
Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient
title Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient
title_full Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient
title_fullStr Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient
title_full_unstemmed Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient
title_short Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient
title_sort favipiravir-induced drug fever in a young adult covid-19 patient
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189533/
https://www.ncbi.nlm.nih.gov/pubmed/34123627
http://dx.doi.org/10.7759/cureus.14928
work_keys_str_mv AT jadejadhigishabam favipiravirinduceddrugfeverinayoungadultcovid19patient
AT patelnirmitr favipiravirinduceddrugfeverinayoungadultcovid19patient

Ejemplares similares